NASDAQ:ACRSAclaris Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aclaris Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.41 +0.07 (+5.22 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$1.31Now: $1.41▼$1.4150-Day Range$1.04MA: $1.25▼$1.4252-Week Range$0.70Now: $1.41▼$5.37Volume236,898 shsAverage Volume190,368 shsMarket Capitalization$59.04 millionP/E RatioN/ADividend YieldN/ABeta1.13 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Aclaris Therapeutics has a potential upside of 254.6% from its current price of $1.41.Amount of Analyst CoverageAclaris Therapeutics has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesAclaris Therapeutics has received 334 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAclaris Therapeutics has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentAclaris Therapeutics has received 52.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote “Outperform” if you believe ACRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.80% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions81.25% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($1.43) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS Previous Symbol CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone484-324-7933Debt Debt-to-Equity Ratio0.18 Current Ratio4.01 Quick Ratio4.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.23 million Price / Sales13.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.39 per share Price / Book1.01Profitability EPS (Most Recent Fiscal Year)($2.25) Net Income$-161,350,000.00 Net Margins-1,490.64% Return on Equity-99.67% Return on Assets-61.01%Miscellaneous Employees169 Outstanding Shares41,870,000Market Cap$59.04 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ACRS Rates by TradingView Receive ACRS News and Ratings via Email Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions How has Aclaris Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACRS shares have increased by 33.0% and is now trading at $1.41. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aclaris Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aclaris Therapeutics. When is Aclaris Therapeutics' next earnings date? Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Aclaris Therapeutics. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics Inc (NASDAQ:ACRS) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.38. The biotechnology company earned $1.41 million during the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative net margin of 1,490.64% and a negative return on equity of 99.67%. View Aclaris Therapeutics' earnings history. What price target have analysts set for ACRS? 4 brokers have issued 1 year price targets for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 254.6% from the stock's current price. View analysts' price targets for Aclaris Therapeutics. Has Aclaris Therapeutics been receiving favorable news coverage? News coverage about ACRS stock has trended negative on Monday, according to InfoTrie. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aclaris Therapeutics earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAclaris Therapeutics. Are investors shorting Aclaris Therapeutics? Aclaris Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,110,000 shares, a decline of 12.8% from the April 30th total of 2,420,000 shares. Based on an average daily trading volume, of 406,800 shares, the days-to-cover ratio is presently 5.2 days. Approximately 6.6% of the shares of the company are sold short. View Aclaris Therapeutics' Current Options Chain. Who are some of Aclaris Therapeutics' key competitors? Some companies that are related to Aclaris Therapeutics include MediciNova (MNOV), Northwest Biotherapeutics (NWBO), Inflarx (IFRX), XOMA (XOMA), Marinus Pharmaceuticals (MRNS), LifeVantage (LFVN), Iterum Therapeutics (NRBO), Aravive (ARAV), Lexicon Pharmaceuticals (LXRX), NuCana (NCNA), IVERIC bio (ISEE), Kalvista Pharmaceuticals (KALV), IDEAYA Biosciences (IDYA), OptiNose (OPTN) and Gemphire Therapeutics (GEMP). View all competitors. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Abeona Therapeutics (ABEO), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Crispr Therapeutics (CRSP), Amicus Therapeutics (FOLD), Nabriva Therapeutics (NBRV) and Progenics Pharmaceuticals (PGNX). Who are Aclaris Therapeutics' key executives? Aclaris Therapeutics' management team includes the following people: Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)Mr. Frank Ruffo, Co-Founder & CFO (Age 53)Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60) What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.28%), Vivo Capital LLC (3.93%), State Street Corp (1.59%), Telemetry Investments L.L.C. (1.20%), JPMorgan Chase & Co. (0.43%) and WINTON GROUP Ltd (0.28%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, James E Flynn, Kamil Ali-Jackson and Stephen A Tullman. View institutional ownership trends for Aclaris Therapeutics. Which institutional investors are selling Aclaris Therapeutics stock? ACRS stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, State Street Corp, JPMorgan Chase & Co., Two Sigma Advisers LP, Alambic Investment Management L.P., and BlackRock Inc.. View insider buying and selling activity for Aclaris Therapeutics. Which institutional investors are buying Aclaris Therapeutics stock? ACRS stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Invesco Ltd., Telemetry Investments L.L.C., Wells Fargo & Company MN, HighTower Advisors LLC, and Nuveen Asset Management LLC. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, and Stephen A Tullman. View insider buying and selling activity for Aclaris Therapeutics. How do I buy shares of Aclaris Therapeutics? Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $1.41. How big of a company is Aclaris Therapeutics? Aclaris Therapeutics has a market capitalization of $59.04 million and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe. What is Aclaris Therapeutics' official website? The official website for Aclaris Therapeutics is www.aclaristx.com. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
